Background: Following hematopoietic stem cell (HSC) transplantation and withdrawal of combination antiretroviral therapy (cART), three previously HIV+patients remain free of measurable replication-competent virus. These results suggest that HSC transplantation represents a promising strategy to induce a functional cure. To better understand the mechanism of HSC-driven HIV control, and apply this therapy to a greater number of patients, we are developing a model of cART-suppressed HIV infection in the pigtailed macaque applicable to both gene therapy- and allogeneic transplant-based cure strategies. Following transplantation of HIV-resistant, autologous cells into conditioned animals, we are evaluating the extent to which protected cell progeny impede infection by SIV/HIV (SHIV) chimeric virus in vivo.
Methodology: Animals are challenged with SHIV virus containing an HIV envelope, after which a 3-drug cART regimen is initiated. Autologous HSCs are engineered to resist infection through transgenic expression of the anti-fusion peptide mC46. Engraftment, persistence, and SHIV response of these autologous stem cells, and stem cell-derived lymphoid and myeloid cells, are measured in vivo.
Results: SHIV infection in the pigtailed macaque model results in sustained viremia with consequent reduction in CD4+ T cells. Moreover, administration of three-drug cART to SHIV-infected animals leads to rapid and durable suppression of plasma viremia to <30 copies/mL plasma – suggesting that this model recapitulates key features of HIV infection and treatment in humans. Transplant of mC46-modified HSCs followed by SHIV infection drives positive selection for mC46-modified cell progeny in peripheral blood and secondary lymphoid tissues, resulting in increased CD4+ T-cell counts and an enhanced SHIVspecific immune response against the challenge virus.
Conclusions: Our pigtailed macaque model of HIV infection and cART represents a promising platform for modeling functional cure strategies, including allogeneic transplant. Here we show that expression of mC46 (one strategy for inhibiting HIV infection) protects T-cells from SHIV-dependent depletion by enabling host immune cells to antagonize spreading infection. These data demonstrate that our pigtailed macaque model is suitable for the pre-clinical evaluation of other functional cure strategies including the knockout of CCR5 by zinc finger nucleases. In addition, this model enables the evaluation of novel therapeutic approaches in the clinically relevant context of cART controlled SHIV infection – a setting of particular importance to approaches aimed at addressing the viral reservoir.